{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:09:15Z","timestamp":1759410555239,"version":"3.37.3"},"reference-count":47,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T00:00:00Z","timestamp":1490659200000},"content-version":"vor","delay-in-days":270,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U01-GM070749","U54-GM111274-01"],"award-info":[{"award-number":["U01-GM070749","U54-GM111274-01"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R37-AI032042"],"award-info":[{"award-number":["R37-AI032042"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.vaccine.2016.05.067","type":"journal-article","created":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T17:53:27Z","timestamp":1466445207000},"page":"3796-3802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Extrapolating theoretical efficacy of inactivated influenza A\/H5N1 virus vaccine from human immunogenicity studies"],"prefix":"10.1016","volume":"34","author":[{"given":"Leora R.","family":"Feldstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Matrajt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Elizabeth Halloran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy A.","family":"Keitel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Ira M.","family":"Longini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.05.067_b0005","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1126\/science.1115717","article-title":"Containing pandemic influenza at the source","volume":"309","author":"Longini","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.05.067_b0010","unstructured":"WPRO|Avian Influenza 2015. <http:\/\/www.wpro.who.int\/emerging_diseases\/AvianInfluenza\/en\/> [accessed September 21, 2015]."},{"key":"10.1016\/j.vaccine.2016.05.067_b0015","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3201\/eid1309.070111","article-title":"Detecting human-to-human transmission of avian influenza A (H5N1)","volume":"13","author":"Yang","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.067_b0020","unstructured":"Highly Pathogenic Avian Influenza (H5N1) Human Cases and Deaths Since 2003 n.d. <http:\/\/www.cdc.gov\/flu\/pdf\/avianflu\/avian-flu-human-world-summary.pdf> [accessed April 9, 2015]."},{"key":"10.1016\/j.vaccine.2016.05.067_b0025","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1073\/pnas.0601266103","article-title":"Mitigation strategies for pandemic influenza in the United States","volume":"103","author":"Germann","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2016.05.067_b0030","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.067_b0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-2659.2012.00349.x","article-title":"An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults","volume":"7","author":"Gillard","year":"2013","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2016.05.067_b0040","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza A\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.05.067_b0045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature04017","article-title":"Strategies for containing an emerging influenza pandemic in Southeast Asia","volume":"437","author":"Ferguson","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.05.067_b0050","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1016\/j.vaccine.2013.09.009","article-title":"A subunit vaccine candidate derived from a classic H5N1 avian influenza virus in China protects fowls and BALB\/c mice from lethal challenge","volume":"31","author":"Liu","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.067_b0055","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1099\/vir.0.058636-0","article-title":"Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models","volume":"95","author":"Park","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.05.067_b0060","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12275-012-1573-z","article-title":"Evaluation of the efficacy of a pre-pandemic H5N1 vaccine (MG1109) in mouse and ferret models","volume":"50","author":"Song","year":"2012","journal-title":"J Microbiol"},{"key":"10.1016\/j.vaccine.2016.05.067_b0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.epidem.2015.06.001","article-title":"One versus two doses: what is the best use of vaccine in an influenza pandemic?","volume":"13","author":"Matrajt","year":"2015","journal-title":"Epidemics"},{"key":"10.1016\/j.vaccine.2016.05.067_b0070","unstructured":"Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. US Dep Heal Hum Serv Food Drug Adm Cent Biol Eval Res 2007. <http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm074786.htm> [accessed October 30, 2015]."},{"key":"10.1016\/j.vaccine.2016.05.067_b0075","first-page":"295","article-title":"The immune response to influenza vaccines","volume":"34","author":"Ghendon","year":"1990","journal-title":"Acta Virol"},{"key":"10.1016\/j.vaccine.2016.05.067_b0080","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis935","article-title":"Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase","volume":"207","author":"Couch","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.067_b0085","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2016.05.067_b0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.virusres.2004.02.025","article-title":"Immunogenicity and protective efficacy of influenza vaccination","volume":"103","author":"Hannoun","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2016.05.067_b0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2288-10-18","article-title":"Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model","volume":"10","author":"Coudeville","year":"2010","journal-title":"BMC Med Res Methodol"},{"year":"1992","series-title":"Infectious diseases of humans","author":"Anderson","key":"10.1016\/j.vaccine.2016.05.067_b0100"},{"key":"10.1016\/j.vaccine.2016.05.067_b0105","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1126\/science.1177373","article-title":"The transmissibility and control of pandemic influenza A (H1N1) virus","volume":"326","author":"Yang","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.05.067_b0110","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/aje\/kwq497","article-title":"Planning for the control of pandemic influenza A (H1N1) in Los Angeles County and the United States","volume":"173","author":"Chao","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.05.067_b0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.epidem.2011.11.003","article-title":"Critical immune and vaccination thresholds for determining multiple influenza epidemic waves","volume":"4","author":"Matrajt","year":"2012","journal-title":"Epidemics"},{"key":"10.1016\/j.vaccine.2016.05.067_b0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0025-5564(02)00129-3","article-title":"The critical vaccination fraction for heterogeneous epidemic models","volume":"181","author":"Hill","year":"2003","journal-title":"Math Biosci"},{"key":"10.1016\/j.vaccine.2016.05.067_b0125","doi-asserted-by":"crossref","first-page":"ofu091","DOI":"10.1093\/ofid\/ofu091","article-title":"Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant","volume":"1","author":"Chen","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.067_b0130","doi-asserted-by":"crossref","first-page":"ofu102","DOI":"10.1093\/ofid\/ofu102","article-title":"Point-of-Use mixing of influenza H5N1 vaccine and MF59 adjuvant for pandemic vaccination preparedness: antibody responses and safety","volume":"1","author":"Mulligan","year":"2014","journal-title":"A Phase 1 Clinical Trial. Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.067_b0135","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","author":"Bernstein","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.067_b0140","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.05.067_b0145","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jiu186","article-title":"Association between antibody titers and protection against influenza virus infection within households","volume":"210","author":"Tsang","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.067_b0150","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1586\/erv.12.63","article-title":"Vaccination against influenza: role and limitations in pandemic intervention plans","volume":"11","author":"Rebmann","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.05.067_b0155","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/archinternmed.2008.513","article-title":"Half- vs full-dose trivalent inactivated influenza vaccine (2004\u20132005): age, dose, and sex effects on immune responses","volume":"168","author":"Engler","year":"2008","journal-title":"Arch Int Med"},{"key":"10.1016\/j.vaccine.2016.05.067_b0160","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/archinte.168.22.2402","article-title":"Half-dose influenza vaccine: stretching the supply or wasting it?","volume":"168","author":"Falsey","year":"2008","journal-title":"Arch Int Med"},{"key":"10.1016\/j.vaccine.2016.05.067_b0165","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0264-410X(01)00440-6","article-title":"Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults","volume":"20","author":"Treanor","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.067_b0170","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa043540","article-title":"Dose sparing with intradermal injection of influenza vaccine","volume":"351","author":"Kenney","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.05.067_b0175","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1371\/journal.pmed.0040218","article-title":"Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate","volume":"4","author":"Riley","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2016.05.067_b0180","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/aje\/kwp072","article-title":"Optimal dosing and dynamic distribution of vaccines in an influenza pandemic","volume":"169","author":"Wood","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.05.067_b0185","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiv087","article-title":"Safety and immunogenicity of a single low dose or high dose of clade 2 influenza A(H5N1) inactivated vaccine in adults previously primed with clade 1 influenza A(H5N1) vaccine","volume":"212","author":"Winokur","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.067_b0190","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.05.067_b0195","first-page":"136","article-title":"A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A\/H5N1 influenza vaccine in adult and elderly subjects","volume":"53","author":"Czajka","year":"2012","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2016.05.067_b0200","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.067_b0205","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1016\/j.vaccine.2009.01.040","article-title":"Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.067_b0210","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2009.10.019","article-title":"Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1\/2 clinical trial","volume":"28","author":"Keitel","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.067_b0215","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2009.10.017","article-title":"Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.067_b0220","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1517\/14712590903066695","article-title":"Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data","volume":"9","author":"Leroux-Roels","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2016.05.067_b0225","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/oxfordjournals.aje.a113408","article-title":"Influenzavirus infections in Seattle families, 1975\u20131979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness","volume":"116","author":"Fox","year":"1982","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.05.067_b0230","first-page":"63","article-title":"Haemagglutination-inhibiting antibody to influenza virus","volume":"115","author":"de Jong","year":"2003","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2016.05.067_b0235","unstructured":"WHO|Influenza 2011. <http:\/\/www.who.int\/influenza\/gisrs_laboratory\/h5n1_nomenclature\/en\/#> [accessed April 9, 2015]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16303930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16303930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T02:37:18Z","timestamp":1655692638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16303930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":47,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0264410X16303930"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.05.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extrapolating theoretical efficacy of inactivated influenza A\/H5N1 virus vaccine from human immunogenicity studies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.05.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}